PubMed:26065608
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/26065608","sourcedb":"PubMed","sourceid":"26065608","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/26065608","text":"Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.\n","tracks":[]}